Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistanceMASSARELLI, Erminia; JOHNSON, Faye M; ERICKSON, Heidi S et al.Lung cancer. 2013, Vol 80, Num 3, pp 235-241, issn 0169-5002, 7 p.Article

Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapyWEIWEI NIE; LIN TANG; HAIYANG ZHANG et al.International journal of oncology. 2012, Vol 40, Num 6, pp 1763-1769, issn 1019-6439, 7 p.Article

Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutationTAJA-CHAYEB, Lucia; CANDELARIA, Myrna; BROM, Rocio et al.Lung cancer. 2005, Vol 50, Num 2, pp 259-263, issn 0169-5002, 5 p.Article

EGFR mutations as a predictive marker of cytotoxic chemotherapyJIN HYUN PARKA; LEE, Se-Hoon; KEAM, Bhumsuk et al.Lung cancer. 2012, Vol 77, Num 2, pp 433-437, issn 0169-5002, 5 p.Article

Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapyGIROUX LEPRIEUR, E; ANTOINE, M; LACAVE, R et al.Lung cancer. 2013, Vol 79, Num 2, pp 167-172, issn 0169-5002, 6 p.Article

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitorsROLFO, Christian; GIOVANNETTI, Elisa; TARON, Mìquel et al.Cancer treatment reviews. 2014, Vol 40, Num 8, pp 990-1004, issn 0305-7372, 15 p.Article

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinibSATOUCHI, M; NEGORO, S; TAKADA, Y et al.British journal of cancer. 2007, Vol 96, Num 8, pp 1191-1196, issn 0007-0920, 6 p.Article

A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancerKAWAHARA, Akihiko; TAIRA, Tomoki; HAYASHI, Akihiro et al.Lung cancer. 2012, Vol 78, Num 1, pp 39-44, issn 0169-5002, 6 p.Article

EGFR-mutated lung cancer in Li-Fraumeni syndromeMICHALAREA, Vasiliki; CALCASOLA, Matthew; CANE, Paul et al.Lung cancer. 2014, Vol 85, Num 3, pp 485-487, issn 0169-5002, 3 p.Article

Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patientsPIRCHER, Andreas; PLONER, Ferdinand; POPPER, Helmut et al.Lung cancer. 2010, Vol 69, Num 3, pp 265-271, issn 0169-5002, 7 p.Article

Rapid communication absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinibCURIGLIANO, Giuseppe; PELOSI, Giuseppe; DE PAS, Tommaso et al.The Prostate. 2007, Vol 67, Num 6, pp 603-604, issn 0270-4137, 2 p.Article

'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancerPALLISL, A. G; VOUTSINA, A; CEORGOULIAS, V et al.British journal of cancer. 2007, Vol 97, Num 11, pp 1560-1566, issn 0007-0920, 7 p.Article

Novel EGFR mutation-specific antibodies for lung adenocarcinoma: Highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistryAN NA SEO; PARK, Tae-In; YAN JIN et al.Lung cancer. 2014, Vol 83, Num 3, pp 316-323, issn 0169-5002, 8 p.Article

EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patientsHONMA, Helen N; PERROUD, Maurício W; LEME, Mauricio S. T et al.Targeted oncology. 2014, Vol 9, Num 4, pp 389-394, issn 1776-2596, 6 p.Article

EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutationsTISEO, M; GELSOMINO, F; BOGGIANI, D et al.Lung cancer. 2011, Vol 71, Num 2, pp 241-243, issn 0169-5002, 3 p.Article

Biological and Clinical Features in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-analysisCHIARA GARASSINO, Marina; BORGONOVO, Karen; FARINA, Gabriella et al.Anticancer research. 2009, Vol 29, Num 7, pp 2691-2701, issn 0250-7005, 11 p.Article

Pulmonary CYP2A13 levels are associated with early occurrence of lung cancer—Its implication in mutagenesis of non-small cell lung carcinomaCHIANG, Huai-Chih; HUEI LEE; CHAO, How-Ran et al.Cancer epidemiology (Print). 2013, Vol 37, Num 5, pp 653-659, issn 1877-7821, 7 p.Article

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)CHEN, G; FENG, J; LU, S et al.Annals of oncology. 2013, Vol 24, Num 6, pp 1615-1622, issn 0923-7534, 8 p.Article

Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation statusKALIKAKI, Aristea; KOUTSOPOULOS, Anastasios; HATZIDAKI, Dora et al.Lung cancer. 2010, Vol 69, Num 1, pp 110-115, issn 0169-5002, 6 p.Article

EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanismPINES, G; HUANG, P. H; ZWANG, Y et al.Oncogene (Basingstoke). 2010, Vol 29, Num 43, pp 5850-5860, issn 0950-9232, 11 p.Article

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progressionREGUART, Noemi; ROSELL, Rafael; CARCERENY, Enric et al.Lung cancer. 2014, Vol 84, Num 2, pp 161-167, issn 0169-5002, 7 p.Conference Paper

CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphismQIANG NIE; YANG, Xue-Ning; WU, Yi-Long et al.European journal of cancer (1990). 2011, Vol 47, Num 13, pp 1962-1970, issn 0959-8049, 9 p.Article

NAT2 fast acetylator genotypes are associated with an increased risk for lung cancer with wildtype epidermal growth factor receptors in TaiwanLEE, Chun-Nin; YU, Ming-Chih; BAI, Kuan-Jen et al.Lung cancer. 2009, Vol 64, Num 1, pp 9-12, issn 0169-5002, 4 p.Article

Prognostic Factors for Gefitinib-Treated Postoperative Recurrence in Non-Small Cell Lung CancerOKAMI, Jiro; TANIGUCHI, Kazuya; HIGASHIYAMA, Masahiko et al.Oncology. 2007, Vol 72, Num 3-4, pp 234-242, issn 0030-2414, 9 p.Article

Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinomaLEE, Soo-Chin; LIM, Seng-Gee; SOO, Ross et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 1, pp 73-74, issn 1744-6872, 2 p.Article